ArticleCancer biomarkers : section A of Disease markers2018
Identification of mannose receptor and CD163 as novel biomarkers for colorectal cancer.
Article in Cancer biomarkers : section A of Disease markers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Prognostic Role of CD68British journal of biomedical science · 2023Pooled it
- Association of intratumoral CD68Frontiers in immunology · 2026Article
- Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments.Signal transduction and targeted therapy · 2025Review
- Regulation and Function of Tumor-Associated Macrophages (TAMs) in Colorectal Cancer (CRC): The Role of the SRIF System in Macrophage Regulation.International journal of molecular sciences · 2025Review
- Prognostic Role of Musashi-2 Immunohistochemical Expression and CD163+ Tumor- Associated Macrophages in Colorectal Cancer Progression.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Correlation between Tregs and ICOS-induced M2 macrophages polarization in colorectal cancer progression.Frontiers in oncology · 2024Article
- Innate IgM antibodies to mannose in patients with gastric cancer.Cancer biology & medicine · 2023Article
- Proteomic Discovery of Plasma Protein Biomarkers and Development of Models Predicting Prognosis of High-Grade Serous Ovarian Carcinoma.Molecular & cellular proteomics : MCP · 2023Article
- Endotoxemia and Gastrointestinal Cancers: Insight into the Mechanisms Underlying a Dangerous Relationship.Microorganisms · 2023Review
- High serum mannose in colorectal cancer: a novel biomarker of lymph node metastasis and poor prognosis.Frontiers in oncology · 2023Article
- Impact of thymidine phosphorylase and CD163 expression on prognosis in stage II colorectal cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Article
- The Prognostic Value of CD206 in Solid Malignancies: A Systematic Review and Meta-Analysis.Cancers · 2021Review
- Role of tumor-associated macrophages at the invasive front in human colorectal cancer progression.Cancer science · 2021Article
- A study of the correlation between M2 macrophages and lymph node metastasis of colorectal carcinoma.World journal of surgical oncology · 2021Article
- Mannose shows antitumour properties against lung cancer via inhibiting proliferation, promoting cisplatin‑mediated apoptosis and reducing metastasis.Molecular medicine reports · 2020Article
- Expression ofTranslational cancer research · 2020Article
- CD163 as a Biomarker in Colorectal Cancer: The Expression on Circulating Monocytes and Tumor-Associated Macrophages, and the Soluble Form in the Blood.International journal of molecular sciences · 2020Article
- Immunosuppressive Phenotype of Esophagus Tumors Stroma.Analytical cellular pathology (Amsterdam) · 2020Article
- Mannose Suppresses the Proliferation and Metastasis of Lung Cancer by Targeting the ERK/GSK-3β/β-Catenin/SNAIL Axis.OncoTargets and therapy · 2020Article
- Elevated CD163International journal of biological sciences · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of present study was to investigate the clinical significances of mannose receptor (MR) and CD163 in colorectal cancer (CRC). Enzyme-linked immunosorbent assay (ELISA) and immunohistochemistry (IHC) were utilized for this analysis. Preoperative serum MR and CD163 levels ranged from 0.153 to 0.804 μg/ml (median = 0.359 μg/ml) and from 0.319 to 1.314 μg/ml (median = 0.685 μg/ml) in CRC patients respectively. Strikingly, preoperative serum levels of MR and CD163 were significantly increased in CRC patients than in healthy individuals (P< 0.0001). ROC analyses suggested that the optimum diagnostic cut-offs for serum MR and CD163 were 0.3485 μg/ml (AUC 0.7205, sensitivity 54.82%, and specificity 80.46%) and 0.6111 μg/ml (AUC 0.7463, sensitivity 62.65%, and specificity 80.46%) respectively. Detection of serum MR and CD163 together obviously enhanced the diagnostic accuracy (AUC 0.7968, sensitivity 69.28%, and specificity 77.01%). Then, preoperative serum MR and CD163 levels correlated significantly with serum CEA, CA19-9 and CA72-4 concentrations in CRC patients (P< 0.05). High MR and CD163 expression in serum was associated significantly with shorter overall survival (P< 0.05) and demonstrated as adversely prognostic factors (P< 0.05). Further, expression of MR and CD163 in CRC tissues was significantly higher than that in para-cancer tissues (P< 0.001). High expression of MR and CD163 in CRC tissues also correlated significantly with shorter overall survival (P< 0.05). MR and CD163 expression in serum or CRC tissues all correlated positively with the degree of lymphatic metastasis (P< 0.0001). In conclusion, MR and CD163 may be novel biomarkers for CRC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.